Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

LONDON, May 9, 2017 /PRNewswire/ -- Report Details
The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.


Download the full report: https://www.reportbuyer.com/product/4890882/



How this report will benefit you
- Read on to discover how you can exploit the future business opportunities emerging in this sector.
- In this brand new 200-page report you will receive 89 tables and 50 figures – all unavailable elsewhere.
- The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.
- By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027

• Submarket forecasts from 2017-2027:
- Biologics
- Aminosalicylates
- Antibiotics
- Corticosteroids
- Immunomodulators

• Revenue forecast from 2017-2027 for 17 leading products:
- Humira
- Remicade
- Lialda
- Asacol
- Pentasa
- Xifaxan
- Cimzia
- Tysabri
- Simponi
- Canasa/Salofalk
- Entyvio
- Apriso
- Medrol
- Neoral
- Entocort
- Uceris
- Azulfidine

• Revenue forecasts from 2017-2027 for 11 countries:
- US
- Japan
- Germany, France, UK, Spain and Italy (EU5)
- Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
- Interleukin (IL) inhibitors
- Cell-adhesion molecule (CAM) inhibitors
- TNF-alpha inhibitors
- Stem cell therapies
- JAK inhibitors
- Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)

Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis.

visiongain is a trading partner with the US Federal Government
Download the full report: https://www.reportbuyer.com/product/4890882/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-inflammatory-bowel-diseases-ibd-drug-market-forecast-2017-2027-300454567.html

SOURCE ReportBuyer